Study wrapper · #517
Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome.
Editor's note
This is a preclinical rat study (120 Sprague-Dawley rats) probing how a low-protein, high-calorie diet interacts with antiretroviral regimens to produce metabolic dysregulation, with tesamorelin included as a co-treatment arm. Researchers reported that the calorie-dense diets combined with integrase-inhibitor or classical regimens were associated with weight gain, elevated glucose and insulin, worse lipids, and hepatic fat accumulation, and that co-administration of tesamorelin (a GHRH analog) was associated with reversal of these effects. Tesamorelin is a supporting element in a diet-drug interaction model. These are preclinical rodent findings — a mechanistic signal consistent with tesamorelin's metabolic profile, not clinical evidence. Human data would be needed before drawing clinical conclusions.
Plain-language abstract
Researchers fed 120 young rats a standard, low-protein high-calorie, or normal-protein high-calorie diet for 15 weeks, then combined the diets with HIV drug regimens for another 9 weeks. The calorie-dense diets — especially the low-protein version — combined with the HIV drugs were associated with weight gain, higher blood sugar and insulin, worse cholesterol, larger livers, and fat buildup in the liver, mirroring the metabolic problems sometimes seen with HIV treatment. Animals that also received tesamorelin, a lab-made growth-hormone-releasing hormone, did not show these metabolic changes. Growth-hormone levels were lower in the groups that did not get tesamorelin. This was an animal study, so the results describe rat biology and cannot be applied directly to people, but they point to the growth-hormone pathway as relevant to diet-and-drug-related metabolic problems.